PRG Pharmaceuticals

PRG Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel small molecule therapeutics for oncology and rare diseases. The company's primary research centers on the Plasticity-Related Gene 1 (PRG-1) pathway, which plays a critical role in lipid signaling and tumor cell migration. Their lead candidate, PRG-101, is designed to inhibit PRG-1 to prevent cancer metastasis and improve outcomes in aggressive solid tumors. By targeting the intersection of neuroscience and oncology, PRG Pharmaceuticals aims to provide first-in-class treatments for patients with limited therapeutic options.